Xilio Therapeutics, Inc.XLOEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 19.90% | 7.3M | — | 2024-04-05 |
| GKCC, LLC | 15.90% | 7.0M | — | 2024-09-27 |
| Bain Capital Life Sciences Fund II, L.P. | 9.99% | 4.6M | — | 2024-11-14 |
| Rock Springs Capital Management LP | 6.83% | 3.0M | ▼ -1.88pp | 2024-11-12 |
| Takeda Pharmaceutical Company Limited | 4.00% | 1.5M | — | 2024-07-31 |
| FMR LLC | 3.17% | 1.4M | — | 2024-11-12 |
| Atlas Venture Fund XI, L.P. | 0.00% | 98.4K | — | 2024-11-14 |
| NOS. OF ABOVE PERSONS | 0.00% | 98.4K | ▼ -6.48pp | 2024-02-06 |
Insider Transactions
Net 90d: +$43.9K · buys $43.9K / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | Director | Buy (open market) | 5.0K | $8.79 | $43.9K |
1–1 of 1